NASDAQ:BJDX Bluejay Diagnostics (BJDX) Stock Price, News & Analysis → Make This $3 Trade the Instant the Opening Bell Rings (From Monument Traders Alliance) (Ad) Free BJDX Stock Alerts $0.84 +0.04 (+5.03%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$0.78▼$0.8750-Day Range$0.75▼$1.0952-Week Range$0.73▼$13.98Volume47,483 shsAverage Volume56,488 shsMarket Capitalization$1.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Bluejay Diagnostics alerts: Email Address Bluejay Diagnostics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.62) to ($2.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.77 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Bluejay Diagnostics. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.16% of the float of Bluejay Diagnostics has been sold short.Short Interest Ratio / Days to CoverBluejay Diagnostics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bluejay Diagnostics has recently increased by 78.26%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBluejay Diagnostics does not currently pay a dividend.Dividend GrowthBluejay Diagnostics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BJDX. Previous Next 2.4 News and Social Media Coverage News SentimentBluejay Diagnostics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Bluejay Diagnostics this week, compared to 0 articles on an average week.Search Interest1 people have searched for BJDX on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Bluejay Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bluejay Diagnostics insiders have not sold or bought any company stock.Percentage Held by Insiders47.00% of the stock of Bluejay Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.52% of the stock of Bluejay Diagnostics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Bluejay Diagnostics are expected to grow in the coming year, from ($5.62) to ($2.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bluejay Diagnostics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bluejay Diagnostics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBluejay Diagnostics has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>> About Bluejay Diagnostics Stock (NASDAQ:BJDX)Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.Read More BJDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BJDX Stock News HeadlinesMarch 13, 2024 | americanbankingnews.comHead to Head Survey: Bluejay Diagnostics (NASDAQ:BJDX) and PetVivo (NASDAQ:PETV)January 2, 2024 | finance.yahoo.comBluejay Diagnostics Announces Closing of $3.5 Million Public OfferingMarch 18, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.December 28, 2023 | marketwatch.comBluejay Diagnostics Shares Slide Premarket After Stock OfferingDecember 28, 2023 | msn.comWhy BlueJay Diagnostics Stock Is FallingDecember 28, 2023 | markets.businessinsider.comBluejay Diagnostics Prices Offering Of 2.692 Mln Shares At $1.30/shrDecember 28, 2023 | msn.comBJDX: SYMON Says: Start the Trial! - MSNDecember 28, 2023 | finance.yahoo.comBJDX: SYMON Says: Start the Trial!March 18, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.December 28, 2023 | finance.yahoo.comBluejay Diagnostics Announces Pricing of $3.5 Million Public OfferingNovember 21, 2023 | msn.comBluejay Diagnostics files to sell common stocks, warrantsNovember 10, 2023 | msn.comBluejay Diagnostics GAAP EPS of -$2.08November 9, 2023 | finance.yahoo.comBluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial ResultsNovember 8, 2023 | finance.yahoo.comBJDX: Toray License RenegotiationOctober 21, 2023 | health.usnews.comBlue adVantage Premier (PPO)October 21, 2023 | health.usnews.comTrue Blue Special Needs Plan (HMO D-SNP)September 20, 2023 | benzinga.comWhat's Going On With Bluejay Diagnostics Stock Today?August 28, 2023 | finance.yahoo.comBJDX: FDA Meeting Confirms PathwayAugust 16, 2023 | finanznachrichten.deBluejay Diagnostics, Inc.: Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial ResultsAugust 16, 2023 | finance.yahoo.comBluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial ResultsAugust 11, 2023 | finance.yahoo.comBluejay Diagnostics Regains Compliance with Nasdaq Minimum Bid Price RequirementAugust 3, 2023 | msn.comDawson James Downgrades Bluejay Diagnostics (BJDX)August 3, 2023 | msn.comBluejay Diagnostics (BJDX) Price Target Increased by 1900.00% to 61.20July 28, 2023 | benzinga.comWhat's Going On With BlueJay Diagnostics Stock?July 24, 2023 | marketwatch.comBluejay Diagnostics Shares Rise 82% After Reverse Stock SplitJuly 24, 2023 | finance.yahoo.comWill Bluejay Diagnostics (NASDAQ:BJDX) Spend Its Cash Wisely?July 21, 2023 | seekingalpha.comBluejay Diagnostics announces 1-for-20 reverse stock split to regain Nasdaq complianceSee More Headlines Receive BJDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bluejay Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/18/2024Next Earnings (Estimated)3/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:BJDX CUSIPN/A CIK1704287 Webwww.bluejaydx.com Phone844-327-7078FaxN/AEmployees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($9.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,300,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-123.99% Return on Assets-97.34% Debt Debt-to-Equity RatioN/A Current Ratio2.33 Quick Ratio2.33 Sales & Book Value Annual Sales$250,000.00 Price / Sales4.14 Cash FlowN/A Price / Cash FlowN/A Book Value$11.45 per share Price / Book0.07Miscellaneous Outstanding Shares1,240,000Free Float657,000Market Cap$1.04 million OptionableNot Optionable Beta0.81 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Indranil Dey (Age 60)President, CEO & Director Comp: $413.16kDr. Jason Cook (Age 41)Chief Technology Officer Comp: $278.42kMs. Frances P. Scally (Age 57)Interim CFO, Principal Financial Officer & Principal Accounting Officer Mr. Les DeLucaVice President of OperationsEryn GrahamMarketing ManagerMr. Kevin Vance (Age 67)Chief Commercial Officer Mark W. FeinbergChief Medical AdvisorDr. Mark W. Feinberg M.D.Chief Medical AdvisorRyan McSeveneyCorporate ControllerMore ExecutivesKey CompetitorsInVivo TherapeuticsNASDAQ:NVIVQuoin PharmaceuticalsNASDAQ:QNRXSintx TechnologiesNASDAQ:SINTMotus GINASDAQ:MOTSReShape LifesciencesNASDAQ:RSLSView All CompetitorsInstitutional OwnershipCitadel Advisors LLCBought 22,077 shares on 2/15/2024Ownership: 1.782%Armistice Capital LLCBought 24,230 shares on 2/13/2024Ownership: 1.954%View All Institutional Transactions BJDX Stock Analysis - Frequently Asked Questions Should I buy or sell Bluejay Diagnostics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bluejay Diagnostics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BJDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BJDX, but not buy additional shares or sell existing shares. View BJDX analyst ratings or view top-rated stocks. How have BJDX shares performed in 2024? Bluejay Diagnostics' stock was trading at $1.22 at the beginning of 2024. Since then, BJDX shares have decreased by 31.5% and is now trading at $0.8356. View the best growth stocks for 2024 here. Are investors shorting Bluejay Diagnostics? Bluejay Diagnostics saw a increase in short interest in the month of February. As of February 29th, there was short interest totaling 24,600 shares, an increase of 78.3% from the February 14th total of 13,800 shares. Based on an average daily volume of 65,800 shares, the short-interest ratio is presently 0.4 days. Approximately 0.2% of the shares of the company are short sold. View Bluejay Diagnostics' Short Interest. When is Bluejay Diagnostics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 18th 2024. View our BJDX earnings forecast. When did Bluejay Diagnostics' stock split? Shares of Bluejay Diagnostics reverse split on Monday, July 24th 2023. The 1-20 reverse split was announced on Monday, July 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Bluejay Diagnostics IPO? (BJDX) raised $22 million in an IPO on Wednesday, November 10th 2021. The company issued 2,160,000 shares at $10.00 per share. Who are Bluejay Diagnostics' major shareholders? Bluejay Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (1.95%) and Citadel Advisors LLC (1.78%). Insiders that own company stock include Douglas Clark Wurth, Gordon Winston Kinder and Kenneth R Fisher. View institutional ownership trends. How do I buy shares of Bluejay Diagnostics? Shares of BJDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BJDX) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bluejay Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.